期刊
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
卷 301, 期 2, 页码 H287-H296出版社
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpheart.00327.2011
关键词
cyclophilin A; oxidative stress; inflammation
资金
- Japanese Ministry of Education, Culture, Sports, Science, and Technology [08107961, 08101562, 09006924, 10002019]
- Japanese Ministry of Health, Labour, and Welfare (Tokyo, Japan) [08005713, 09158526, 10102895]
- MEXT, Japan
- Grants-in-Aid for Scientific Research [22390154, 23659408] Funding Source: KAKEN
Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 301: H287-H296, 2011. First published May 27, 2011; doi:10.1152/ajpheart.00327.2011.-Rho-kinase (ROCKs) belongs to the family of serine/threonine kinases and is an important downstream effector of the small GTP-binding protein RhoA. There are two isoforms of Rho-kinase, ROCK1 and ROCK2, and they have different functions with ROCK1 for circulating inflammatory cells and ROCK2 for vascular smooth muscle cells. It has been demonstrated that the RhoA/Rho-kinase pathway plays an important role in various fundamental cellular functions, including contraction, motility, proliferation, and apoptosis, leading to the development of cardiovascular disease. The important role of Rho-kinase in vivo has been demonstrated in the pathogenesis of vasospasm, arteriosclerosis, ischemia-reperfusion injury, hypertension, pulmonary hypertension, stroke, and heart failure. Furthermore, the beneficial effects of fasudil, a selective Rho-kinase inhibitor, have been demonstrated for the treatment of several cardiovascular diseases in humans. Thus the Rho-kinase pathway is an important new therapeutic target in cardiovascular medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据